Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher partcipant assessment of success compared with placebo (moderate certainty).
Summary of Findings Table ‐ IncobotulinumtoxinA 20U probably leads to higher participant assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
Summary of Findings Table ‐ IncobotulinumtoxinA 20U probably leads to higher physician assessment of success by analysing scores and scales compared with placebo (moderate certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in participant assessment success by analysing scores and scales ‐ 4… compared with onabotulinumtoxinA 20U (high certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in physician assessment of success by analysing scores and scales ‐ 4… compared with onabotulinumtoxinA 20U (high certainty).
The review found no eligible studies for this question.
Summary of Findings Table ‐ IncobotulinumtoxinA 24U showed no clear difference in physician assessment of success by analysing scores and scales ‐ 4… compared with onabotulinumtoxinA 24U (low certainty).
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher participant assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher physician assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher physician assessment of success compared with placebo (moderate certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U leads to higher participant assessment of success by analysing scores and scales ‐… compared with placebo (high certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U probably leads to higher physician assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
It is very uncertain whether summary of findings table ‐ NB‐UVB changes investigator Global Assessment compared with PUVA (very low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ NB‐UVB may leads to higher investigator Global Assessment (short‐term) compared with placebo (low certainty).
The review found no eligible studies for this question.
Benzoyl peroxide may leads to higher participant's global self‐assessment of improvement (long‐term data) compared with placebo or no treatment (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Benzoyl peroxide showed no clear difference in participant's global self‐assessment of improvement (long‐term data) compared with adapalene (low certainty).